UMU logo

Open position: PostDoc Project in In vivo efficacy and mode of action of novel antimicrobials acting against intracellular bacteria

The Sixt lab at MIMS is looking for a postdoc to join the group and advance them at the field of Chlamydia research. 

Project: The extensive use of broad-spectrum antibiotics is a major aggravator of the alarming spread of antimicrobial resistances. Moreover, it impacts patient health negatively by its devastating collateral effects on the microbiota. Hence, there is an urgent need for more selective treatment options. Using an innovative antimicrobial discovery approach, we have recently identified a set of compounds displaying narrow-spectrum activity against Chlamydia, a group of obligate intracellular bacteria that every year causes millions of cases of urogenital, ocular, and respiratory infections. The purpose of this project is to determine in vivo efficacy and selectivity of our most potent compounds, and to determine their molecular targets and mode of interference with the intracellular growth and development of the pathogen.

Applications are possible from now until a suitable candidate was found. Starting date: preferentially between late 2022 and early 2023 (can be negotiated).

Environment: This project represents a collaboration between two research groups (the groups of Barbara Sixt and Åsa Gylfe) at Umeå University (located in Umeå, Sweden). The recruited postdoc will be affiliated primarily with the Sixt Lab, which is part of the Laboratory for Molecular Infection Medicine Sweden (MIMS). MIMS in turn is a part of the Nordic EMBL Partnership for Molecular Medicine and of the Umeå Centre for Microbial Research (UCMR), providing a stimulating, collaborative, and highly international environment with excellent access to modern research facilities. The city Umeå itself combines a rich cultural life with exceptional closeness to nature and is particularly welcoming to internationals.

Qualifications: Candidates must hold a University degree equivalent to a European University PhD degree in molecular biology, cell biology, or infection biology (or equivalent fields) at the time of the recruitment. To be eligible, applicants should have completed their PhD degree a maximum of three years before the end of the application period, unless special circumstances exist. Candidates must have documented practical experience in molecular techniques, mammalian cell culture, and in vivo experimentation (mouse model). Previous practical experience in working with intracellular pathogens and in determining molecular mechanisms of host-pathogen interactions is a desirable skill. Candidates should be passionate about science, willing to take on scientific challenges, and committed to highest quality research. Candidates are expected to be proficient in written and spoken English, to work as part of an interactive team, to participate in the mentoring of less experienced team members, and in particular to have the capacity to individually develop and drive a research project.

Project duration: 2 years (with possibility for further prolongation depending on satisfactory performance)

Starting date: preferentially between late 2022 and early 2023 (can be negotiated)

Application: Interested candidates are welcome to send an application to This email address is being protected from spambots. You need JavaScript enabled to view it.. Applications should include (as a single PDF file in English): 1) a letter of motivation describing the applicant’s specific motivation and relevant qualifications, 2) a curriculum vitae, 3) a publication list (if applicable) and 4) names and e-mail addresses of two or more references, with stated professional relationship to the applicant. Applications are possible from now until a suitable candidate was found.

To find out more about the lab and research environment, visit the following websites:
• The Sixt Lab: http://www.sixtlab.org
• The Gylfe Lab: https://www.umu.se/en/staff/asa-gylfe/
• The Laboratory for Molecular Infection Medicine Sweden (MIMS): http://www.mims.umu.se
• Nordic EMBL Partnership for Molecular Medicine: https://projects.au.dk/nordic-embl-partnership/
• Umeå Centre for Microbial Research (UCMR): http://www.ucmr.umu.se
• Umeå University: http://www.umu.se/en

MIMS Symposium 11 November 2022

Emmanuelle Charpentier took the Nobel Prize in Chemistry

Emmanuelle has been awarded jointly with Jennifer Doudna the 2020 Nobel Prize in Chemistry for discovering the groundbreaking CRISPR-Cas9 gene editing technology. She is a former group leader at MIMS, honorary doctor at Umeå University and former visiting professor at UCMR.

Movie by Knut and Alice Wallenberg Foundation (https://kaw.wallenberg.org/)

MIMS is characterized by
ECharpentier about MIMS 2015 1

Emmanuelle Charpentier, Alumna at MIMS, Director of the Max Planck Unit for the Science of Pathogens, Berlin, Germany.

Link to the Emmanuelle Charpentier Lab

Battling antibiotic resistance

movie by Knut and Alice Wallenberg Foundation, with participation of scientists from MIMS and UCMR:
Or watch the original movie on:
https://kaw.wallenberg.org/

Research about infectious diseases:

Oliver Billker in movie of Knut and Alice Wallenberg Foundation:
Or watch the original movie on:
https://kaw.wallenberg.org/

Emmanuelle Charpentier
about her research at MIMS

footer all slides 2014-02-06


Copyright © 2019 by The Laboratory for Molecular Infection Medicine Sweden (MIMS). All rights reserved.